{"id":"W2136139191","doi":"10.1177/1352458508097299","title":"Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results","year":2008,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Institutes of Health","keywords":"Medicine; Tolerability; Immunogenicity; Interferon beta-1a; Multiple sclerosis; Confidence interval; Adverse effect; Internal medicine; Clinical endpoint; Clinical trial; Antibody; Gastroenterology; Immunology; Interferon beta","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001487253,0.0005200197,0.001414609,0.001126393,0.0003470811,0.0000473208,0.000299835,0.0002997083,0.00003291351],"category_scores_gemma":[0.00245171,0.000434061,0.000221926,0.001166347,0.000188244,0.001019421,0.0002788348,0.001422737,0.000002507907],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006235132,"about_ca_system_score_gemma":0.0004558307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003119361,"about_ca_topic_score_gemma":0.002974302,"domain_scores_codex":[0.9940234,0.0003281253,0.002715241,0.0006608754,0.00148053,0.0007917851],"domain_scores_gemma":[0.9964269,0.000604449,0.001171118,0.0005942195,0.0007087329,0.0004945545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.05701718,0.004923689,0.8773617,0.00007473196,0.0002812739,0.00001007593,0.01197923,0.001056215,0.02138409,0.000001030367,0.0001150823,0.02579568],"study_design_scores_gemma":[0.125688,0.006767041,0.8549139,0.002564924,0.00008831995,0.00001465547,0.001140155,0.005826022,0.002658325,0.000006788027,0.00002070638,0.0003111529],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956423,0.0004727703,0.0009025279,0.0002214124,0.0001126686,0.002504644,0.00007558193,0.0000314477,0.00003661637],"genre_scores_gemma":[0.9942538,0.00104346,0.004374981,0.00002964557,0.0001021041,0.00001987706,0.0000567514,0.00006824973,0.00005113148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0686708,"threshold_uncertainty_score":0.9998111,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1209235769177282,"score_gpt":0.3048185937232836,"score_spread":0.1838950168055554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}